L19TNFα in Patients With Advanced Solid Tumors

The recombinant human fusion protein L19TNFα was created with the intention to overcome the systemic toxicity of TNFα by directly targeting it to tumor tissues. Tumor-targeted L19TNFα would result in high and sustained intralesional bioactive TNFα concentrations.

重组人融合蛋白L19TNFα的设计初衷，是通过将肿瘤坏死因子α（TNFα）直接靶向递送至肿瘤组织，以克服其全身性毒性。经肿瘤靶向递送的L19TNFα，可在病灶内形成高浓度且持续稳定的生物活性TNFα水平。